University of Baghdad

HII Names New Chief Growth Officer for Mission Technologies Division

Retrieved on: 
Friday, August 18, 2023
HII, Green, Organization, University of Baghdad, Southern New Hampshire University, Economic development, Mantech, Management

MCLEAN, Va., Aug. 18, 2023 (GLOBE NEWSWIRE) -- HII’s Mission Technologies division has hired Ahmed Ayad to serve as chief growth officer.

Key Points: 
  • MCLEAN, Va., Aug. 18, 2023 (GLOBE NEWSWIRE) -- HII’s Mission Technologies division has hired Ahmed Ayad to serve as chief growth officer.
  • Reporting to Andy Green, HII executive vice president and president of HII’s Mission Technologies division, Ayad is responsible for shaping and implementing the division’s growth strategy and driving compelling solutions to its customers’ most complex national security challenges.
  • With Ahmed onboard and our strong momentum, I’m confident Mission Technologies will continue to serve as a growth engine for HII and I look forward to our bright future.”
    Ayad recently supported ManTech, where he served as vice president and growth lead for the defense sector since 2019.
  • He previously supported other organizations across the industry in strategic capture and senior growth roles.

CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants

Retrieved on: 
Tuesday, December 7, 2021
Human, University of Geneva, Research, Delta, Plasma protein binding, Niclosamide, COVID-19, KOSDAQ, Technology, Hospital, Mutation, University of Oxford, Omicron, Drug resistance, Thought, CP, Space Delta 6, Vaccine, Yale University, COVID, Patient, Cell, Method, Organization, DDS, University of California, San Francisco, Virus, Korea Research Institute of Bioscience and Biotechnology, CEO, Science (journal), Degenerative disease, Trial of the century, University of Baghdad, University, RNA, KRIBB, Autophagy, Clinical trial, Interview, Immunity, CTO, PLOS, Severe acute respiratory syndrome coronavirus 2, WHO, Pharmaceutical industry

SEOUL, South Korea, Dec. 7, 2021 /PRNewswire/ -- Experimental results have been published for the first time showing that an antiviral drug containing niclosamide, an anthelmintic, in combination with dexamethasone, an anti-inflammatory drug, produces a 'synergistic effect' for severe COVID-19 patients. There is a growing possibility that a combination therapy for severe COVID-19 patients, for which there is currently no suitable treatment, may be developed for the first time in Korea.

Key Points: 
  • CP-COV03, a niclosamide-based oral antiviral drug, to cure COVID-19 variants
    CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19.
  • It is a 'host-directed' drug that focuses on the host cell, unlike existing vaccines and antiviral drugs that target the virus.
  • This is the first study result that confirmed the synergistic effect of an oral antiviral drug with dexamethasone as COVID-19 combo treatment.
  • Dr. Kim also stated, "Because CP-COV03 targets host cells, it will be a broad-spectrum antiviral drug that can treat COVID-19 and its variants."